PRODUCT INFORMATION



PQR530

Item No. 28563

CAS Registry No.: 1927857-61-1

Formal Name: 4-(difluoromethyl)-5-[4-[(3S)-3-methyl-

4-morpholinyl]-6-(4-morpholinyl)-1,3,5-

triazin-2-yl]-2-pyridinamine


MF: $C_{18}H_{23}F_2N_7O_2$

407.4 FW: ≥98% **Purity:**

UV/Vis.: λ_{max} : 235, 290 nm A crystalline solid Supplied as:

Storage: -20°C Stability: ≥4 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.



Laboratory Procedures

PQR530 is supplied as a crystalline solid. A stock solution may be made by dissolving the PQR530 in the solvent of choice, which should be purged with an inert gas. PQR530 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of PQR530 in these solvents is approximately 10 and 30 mg/ml, respectively.

PQR530 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, PQR530 should first be dissolved in DMF and then diluted with the agueous buffer of choice. PQR530 has a solubility of approximately 0.33 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

PQR530 is a dual inhibitor of PI3K α and mammalian target of rapamycin (mTOR; IC $_{50}$ s = 11.1 and 7.4 nM, respectively). It inhibits phosphorylation of Akt and ribosomal S6 kinase in A2058 melanoma cells (IC₅₀s = 62.2 and 61.1 nM, respectively). PQR530 inhibits cell growth in a panel of 66 cancer cell lines (mean GI_{50} = 0.43 μ M). In vivo, PQR530 (25 mg/kg) reduces tumor growth in an OVCAR-3 ovarian cancer mouse xenograft model. It decreases the number of seizures per week in a Tsc1^{GFAP} conditional knockout mouse model of epilepsy.²

References

- 1. Rageot, D., Bohnacker, T., Keles, E., et al. (S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a potent, orally bioavailable and brain penetrable dual inhibitor of class I PI3K and mTOR kinase. J. Med. Chem. 62(13), 6241-6261 (2019).
- 2. Theilmann, W., Gericke, B., Schidlitzki, A., et al. Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. Neuropharmacology 180, 108297 (2020).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information Buyer agrees to purchase the mater can be found on our website.

Copyright Cayman Chemical Company, 10/11/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.**CAYMANCHEM**.COM